Abstract

We estimated the size of the population of gay-identified men who have sex with men (gay men) eligible for PrEP in Australia under the current national PrEP guidelines. Using input indicators from the Australian Bureau of Statistics, the national representative survey Second Australian Study of Health and Relationships, and national HIV- behavioural surveillance, we calculated the size of the population of sexually active gay men and estimated a range for the number eligible for PrEP using different scenarios based on the guidelines. In 2015, an estimated 108,850 sexually-active 16-69-year-old gay men were classified as at risk of acquiring HIV in Australia. Of these men, 10,558 to 30,913 (9.7%-28.4%) were classified as being at high risk and therefore eligible for PrEP, most commonly due to recent receptive condomless intercourse with casual partners (6.1% to 15.5%), STI infections (5.4% to 10.6%) or the use of crystal methamphetamine (1.4% to 9.4%). The higher estimates included men who may have been at HIV risk for shorter time periods or with fewer partners. Australian PrEP guidelines recommend targeting PrEP to people at high HIV risk. Our estimation of potential PrEP users informed PrEP implementation in Australia. The choice of PrEP eligibility criteria, and interpretation of the guidelines, strongly affects the population estimates. In the future, higher numbers of gay men may become eligible for PrEP, because the estimates are largely defined by and follow trends in condomless anal intercourse. Our estimation methods can be adapted to other settings.

Highlights

  • Co-formulated tenofovir disoproxil fumarate and emtricitabine, (TDF/FTC, marketed as Truvada1 [1]) has been widely used for HIV treatment

  • This paper presents the estimate of potential pre-exposure prophylaxis (PrEP) users to inform consideration of submissions for Pharmaceutical Benefits Scheme (PBS) listing of PrEP and to inform planning of PrEP access studies in various Australian States/Territories referred to earlier

  • We identified men at high risk of acquiring HIV, defined by 2015 Australian PrEP guidelines [17]

Read more

Summary

Introduction

Co-formulated tenofovir disoproxil fumarate and emtricitabine, (TDF/FTC, marketed as Truvada1 [1]) has been widely used for HIV treatment. In 2015, two landmark European trials, IPERGAY and PROUD, each reported an 86% HIV-risk reduction due to the use of TDF/FTC as PrEP in men who have sex with men at high risk for HIV infection [5, 6]. Results from these two studies alleviated concerns about possible poor PrEP adherence among high HIV-risk people and brought about a turning point in PrEP implementation. This paper presents the estimate of potential PrEP users to inform consideration of submissions for PBS listing of PrEP and to inform planning of PrEP access studies in various Australian States/Territories referred to earlier

Materials and methods
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call